Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07928258
PHASE1

A Study of LY4336619 in Adult Participants With Advanced Solid Tumors

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to evaluate how safe and effective LY4336619 is in adults with advanced cancer. Some participants will receive LY4336619 alone, and some will receive it with another cancer medicine. Participants will be in the study for up to 2 years, depending on how they tolerate and respond to treatment.

Official title: A First-in Human, Phase 1 Trial to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LY4336619, an Alkaline Phosphatase Placental-Like 2 (ALPPL2) T- Cell Engager Bispecific Antibody, in Adult Participants With Advanced Solid Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

370

Start Date

2026-12

Completion Date

2032-03

Last Updated

2026-11-10

Healthy Volunteers

No

Interventions

DRUG

LY4336619

Administered IV

DRUG

Sofetabart Mipitecan (Sofe-M)

Administered IV

Locations (23)

HonorHealth

Scottsdale, Arizona, United States

City of Hope

Duarte, California, United States

University of California, San Diego (UCSD) - Moores Cancer Center

La Jolla, California, United States

The University of Chicago Medical Center (UCMC)

Chicago, Illinois, United States

Harvard Medical School - Massachusetts General Hospital (MGH) - Cancer Center

Boston, Massachusetts, United States

South Texas Accelerated Research Therapeutics (START) - New York - Long Island

Lake Success, New York, United States

New York University (NYU) Clinical Cancer Center

New York, New York, United States

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

New York, New York, United States

The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Rese -T

Columbus, Ohio, United States

MD Anderson Cancer Center

Houston, Texas, United States

START Mountain Region

West Valley City, Utah, United States

Centre Leon Berard

Lyon, France

Institut de Cancerologie de l'Ouest - site St-Herblain

Saint-Herblain, France

Oncopole Claudius Regaud

Toulouse, France

Institut Gustave Roussy

Villejuif, France

Shizuoka Cancer Center

Shizuoka, Japan

National Cancer Center Hospital

Tokyo, Japan

Cancer Institute Hospital of JFCR

Tokyo, Japan

Hospital Universitario Vall d'Hebron

Barcelona, Spain

Clinica Universidad de Navarra - Madrid

Madrid, Spain

Hospital Universitario 12 de Octubre

Madrid, Spain

The Christie NHS Foundation Trust

Manchester, United Kingdom

Royal Marsden Hospital - Surrey

Sutton, United Kingdom